SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

73.90

-0.73 (-0.98%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	74.63
Open	73.91
Bid	0.00 x 800
Ask	0.00 x 800
Day's Range	73.27 - 74.23
52 Week Range	45.31 - 74.72
Volume	469,686
Avg. Volume	858,229

Market Cap	11.735B
Beta	2.00
PE Ratio (TTM)	N/A
EPS (TTM)	-0.30
Earnings Date	Oct 24, 2018 - Oct 29, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	75.80

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks2 days ago
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Markit2 days ago
See what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
Motley Fool2 days ago
(UMRX) Q2 2018 Earnings Conference Call Transcript
UMRX earnings call for the period ending June 30, 2018.
Thomson Reuters StreetEvents2 days ago
Edited Transcript of SGEN earnings conference call or presentation 26-Jul-18 8:30pm GMT
Q2 2018 Seattle Genetics Inc Earnings Call
Markit5 days ago
See what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
Zacks6 days ago
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Zacks7 days ago
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
Zacks7 days ago
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Zacks7 days ago
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
Zacks7 days ago
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
Zacks8 days ago
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2
The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.
Zacks8 days ago
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
Zacks8 days ago
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
Zacks9 days ago
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
Market Realist10 days ago
How Neurocrine Biosciences Performed in the Second Quarter
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.
Market Realist10 days ago
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.
Market Realist13 days ago
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.
Zacks14 days ago
Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y
The Medicines Company (MDCO) beats earnings estimates while missing the same for revenues in the second quarter.
Zacks14 days ago
Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track
Ophthotech reports narrower-than-expected loss in the second quarter.
Zacks14 days ago
Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Motley Fool15 days ago
Seattle Genetics' Latest Approval Is the Best Yet
Frontline treatment of Hodgkin lymphoma drives Adcetris sales to new heights.
Market Realist15 days ago
Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018, compared to estimates for EPS of $0.34 on revenues of $473.8 million.
Zacks20 days ago
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
Benzinga20 days ago
Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...
Market Realist20 days ago
Seattle Genetics Increased Its Fiscal 2018 Outlook
During the second-quarter earnings release, Seattle Genetics updated the progress of its product pipeline programs. The company has its Adcetris product under Phase 3 trial for use in frontline PTCL (peripheral T-cell lymphoma). The results are expected early in the fourth quarter. Enfortumab Vedotin is another drug under Phase 3 trial to treat patients with locally advanced or metastatic urothelial cancer. Seattle Genetics is developing Tucatinib to treat HER2-positive (HER2+) metastatic breast cancer patients. ...